Patients with HFimpEF have improved prognosis but nonetheless remain at risk of relapse and long-term adverse events. Future studies will hopefully chart the natural history of HFimpEF and identify clinical predictors such as blood or novel imaging biomarkers that distinguish subgroups of patients based on differential trajectory and prognosis.
Keyphrases
- ejection fraction
- aortic stenosis
- heart failure
- end stage renal disease
- left ventricular
- high resolution
- newly diagnosed
- chronic kidney disease
- free survival
- peritoneal dialysis
- atrial fibrillation
- mass spectrometry
- photodynamic therapy
- acute heart failure
- patient reported
- fluorescence imaging
- transcatheter aortic valve replacement
- case control